EURONEXT-PAR$SNY
Sanofi · Q3 2025 earnings
Q3 2025 earnings · · Investor relations
Briefing
Sanofi reported solid earnings in Q3 2025, driven by strong performance from Dupixent and new pharma launches despite a decline in vaccine sales.
Sanofi delivered profitable growth in Q3 2025, with business EPS reaching €2.91 and total revenue of €12.43 billion. Net income remained stable, while Dupixent sales exceeded €4 billion for the first time. Vaccine sales declined due to flu-related weakness.
- Business EPS was €2.91, up 13.2% at constant exchange rates
- Revenue grew 7.0% at CER to €12.43 billion
- Dupixent sales rose 26.2% YoY to €4.2 billion
- Vaccine sales declined 7.8% YoY due to lower influenza sales
Headline financials
Revenue & EPS history
Sanofi · Revenue · Quarterly
$14.6B
Revenue by segment
Sanofi · $6.67B total across 3 segments · Q1 2026
- Dupixent$4.2B—63.0%
- Vaccines$1.3B—19.5%
- Pharma launches$1.17B—17.6%
Forward guidance
Sanofi reaffirmed its full-year 2025 guidance, expecting high single-digit sales growth and low double-digit business EPS growth at CER.
Tailwinds
- Dupixent continued strong momentum
- New launches contributed significantly to revenue
- Operational efficiency improved profitability
- Positive pipeline milestones with new approvals
- Share buyback program near completion
Headwinds
- Vaccine sales weakened due to flu market softness
- Currency impact remained unfavorable
- Free cash flow declined 6.1% YoY in Q3
- SG&A expenses increased to support launches
- R&D spend increased despite prioritization
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2025
-0.5%
Avg return
Earnings day
-0.3%
Avg return
5 days after
+1.5%
Avg return
30 days after
44%
17 / 39 earnings
Positive
+6.1%
Q4 2016
Best reaction
-15.9%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.0% | -2.0% | +64.0% | |
| Q3 2025 | +2.2% | +1.6% | -1.5% | |
| H1 2025 | -6.4% | -2.9% | +0.5% | |
| Q2 2024 | +2.3% | +1.0% | +9.8% | |
| Q4 2023 | -5.4% | -5.7% | -5.2% | |
| Q3 2023 | -15.9% | -13.1% | -11.5% | |
| Q2 2023 | -0.3% | -3.8% | -0.2% | |
| Q1 2023 | -4.6% | -5.1% | -6.6% | |
| Q4 2022 | -2.9% | +1.0% | +1.1% | |
| Q3 2022 | +4.0% | +3.3% | +9.2% | |
| Q2 2022 | -2.4% | -4.2% | -19.8% | |
| Q1 2022 | -3.8% | -1.7% | +1.5% | |
| Q4 2021 | +1.1% | +2.3% | -7.6% | |
| Q2 2021 | -1.0% | +4.8% | -2.6% | |
| Q3 2021 | +1.7% | +4.8% | -2.6% | |
| Q1 2021 | +2.2% | -1.1% | -0.4% | |
| Q4 2020 | +3.2% | +2.0% | -1.1% | |
| Q2 2020 | +1.3% | +3.1% | +10.8% | |
| Q3 2020 | -1.8% | +3.1% | +10.8% | |
| Q1 2020 | +4.7% | -2.6% | -2.5% | |
| Q4 2019 | +3.5% | +3.9% | -1.8% | |
| Q3 2019 | -3.8% | -3.8% | -1.6% | |
| Q2 2019 | -0.7% | -2.5% | +1.6% | |
| Q1 2019 | +5.2% | +5.3% | +2.6% | |
| Q4 2018 | -1.7% | -1.5% | -1.1% | |
| Q3 2018 | +4.4% | +3.6% | +4.9% | |
| Q2 2018 | +2.2% | +0.2% | +1.4% | |
| Q1 2018 | -2.6% | -3.5% | -5.2% | |
| Q4 2017 | -6.2% | -6.0% | -4.1% | |
| Q3 2017 | -1.6% | -1.9% | -4.0% | |
| Q2 2017 | -1.1% | +1.1% | +1.3% | |
| Q1 2017 | +0.7% | +1.9% | +4.5% | |
| Q4 2016 | +6.1% | +5.7% | +9.1% | |
| Q3 2016 | +4.4% | +6.7% | +7.0% | |
| Q2 2016 | -0.3% | -3.9% | -8.9% | |
| Q1 2016 | -3.2% | — | — | |
| Q4 2015 | -1.8% | — | — | |
| Q3 2015 | -2.2% | — | — | |
| Q2 2015 | +2.6% | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro